BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Accenture
US Army
Moodys
Mallinckrodt
Citi
Queensland Health
Cipla
Novartis

Generated: January 16, 2018

DrugPatentWatch Database Preview

Speciality European Company Profile

« Back to Dashboard

What is the competitive landscape for SPECIALITY EUROPEAN, and what generic alternatives to SPECIALITY EUROPEAN drugs are available?

SPECIALITY EUROPEAN has one approved drug.

There are three US patents protecting SPECIALITY EUROPEAN drugs.

There are fifty-nine patent family members on SPECIALITY EUROPEAN drugs in thirty-four countries and five supplementary protection certificates in five countries.

Summary for Speciality European
International Patents:59
US Patents:3
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Speciality European

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Speciality European

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 ➤ Subscribe ➤ Subscribe
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 ➤ Subscribe ➤ Subscribe
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 ➤ Subscribe ➤ Subscribe
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 ➤ Subscribe ➤ Subscribe
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 ➤ Subscribe ➤ Subscribe
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Premature patent expirations for SPECIALITY EUROPEAN

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Subscribe ➤ Subscribe

International Patents for Speciality European Drugs

Supplementary Protection Certificates for Speciality European Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90014-9 Sweden ➤ Subscribe PRODUCT NAME: ABARELIX
2011 00004 Denmark ➤ Subscribe PRODUCT NAME: ABARELIX, EVENTUELT I FORM AF ET FARMACEUTISK SALT; NAT. REG. NO/DATE: 44637 (DK) 20100827; FIRST REG. NO/DATE: DE 578900000 20050922
C0015 France ➤ Subscribe PRODUCT NAME: ABARELIX, EVENTUELLEMENT SOUS FORME DE SEL PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE IN FRANCE: 69026150 DU 20101126; REGISTRATION NO/DATE AT EEC: 57890.00.00 DU 20050922
C/GB11/006 United Kingdom ➤ Subscribe PRODUCT NAME: ABARELIX, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: DE - 20050922; UK PL32828/001 20100917
00484 Netherlands ➤ Subscribe PRODUCT NAME: ABARELIX, EVENTUEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 104389 20101220; FIRST REGISTRATION: 57890.00.00 20050922
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Julphar
Queensland Health
Deloitte
McKinsey
Baxter
Mallinckrodt
McKesson
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot